A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

Helus Pharma™, a subsidiary of Cybin Inc. (NASDAQ: HELP) (Cboe CA: HELP), has announced that its APPROACH Phase 3 trial for HLP003, aimed at providing adjunctive treatment for major depressive disorder, has achieved over 86% enrollment. The company is progressing well towards meeting the requirements set by the FDA for the trial.